uniQure (NASDAQ:QURE) Shares Gap Down – What’s Next?

by · The Cerbat Gem

uniQure N.V. (NASDAQ:QUREGet Free Report) gapped down before the market opened on Thursday . The stock had previously closed at $25.48, but opened at $21.25. uniQure shares last traded at $22.6410, with a volume of 4,031,125 shares.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on QURE. Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a research note on Sunday. Weiss Ratings restated a “sell (d-)” rating on shares of uniQure in a research report on Wednesday, October 8th. Wells Fargo & Company lowered their price target on shares of uniQure from $80.00 to $60.00 and set an “overweight” rating for the company in a report on Wednesday, November 12th. UBS Group set a $95.00 price objective on uniQure in a report on Thursday, September 25th. Finally, Cantor Fitzgerald boosted their price objective on uniQure from $47.00 to $80.00 and gave the stock an “overweight” rating in a research report on Thursday, September 25th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $64.42.

Read Our Latest Stock Report on QURE

uniQure Trading Down 10.4%

The company has a market cap of $1.42 billion, a P/E ratio of -5.19 and a beta of 0.59. The firm’s 50 day moving average is $45.82 and its two-hundred day moving average is $26.07. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.23.

uniQure (NASDAQ:QUREGet Free Report) last announced its earnings results on Monday, November 10th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.53). uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%.The company had revenue of $3.70 million for the quarter, compared to analyst estimates of $4.46 million. As a group, equities research analysts anticipate that uniQure N.V. will post -3.75 EPS for the current year.

Insider Activity

In other news, Director Jack Kaye sold 38,810 shares of the business’s stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $30.34, for a total value of $1,177,495.40. Following the transaction, the director owned 20,439 shares in the company, valued at approximately $620,119.26. The trade was a 65.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Matthew C. Kapusta sold 226,316 shares of the stock in a transaction on Wednesday, September 24th. The stock was sold at an average price of $41.46, for a total transaction of $9,383,061.36. Following the sale, the chief executive officer owned 651,454 shares of the company’s stock, valued at approximately $27,009,282.84. This trade represents a 25.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 314,560 shares of company stock worth $12,362,568 in the last 90 days. 4.79% of the stock is owned by company insiders.

Institutional Trading of uniQure

Several large investors have recently modified their holdings of QURE. CIBC Private Wealth Group LLC bought a new stake in shares of uniQure in the 3rd quarter valued at $50,000. Financial Engines Advisors L.L.C. acquired a new stake in uniQure in the third quarter worth $278,000. Alyeska Investment Group L.P. bought a new stake in uniQure in the third quarter valued at $2,335,000. Velan Capital Investment Management LP bought a new stake in uniQure in the third quarter valued at $1,868,000. Finally, Sassicaia Capital Advisers LLC acquired a new position in shares of uniQure during the third quarter valued at about $934,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Company Profile

(Get Free Report)

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

Recommended Stories